An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia

Trial Identifier: D9481C00001
Sponsor: AstraZeneca
Collaborator:
Not Applicable
Start Date: April 2019
Primary Completion Date: June 2026
Study Completion Date: June 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BR Campinas, BR, 13060-904
BR Sao Paulo, BR, 01228-200
BR São Paulo, BR, 04038-002
CA, AB Calgary, AB, CA, T3B 6A8
CA, QC Montréal, QC, CA, H3T1C5
CN Beijing, CN, 100045
CN Beijing, CN, 100034
CN Changsha, CN, 410007
CN Chengdu, CN, 610000
CN Chengdu, CN, 610041
CN Chongqing, CN, 400014
CN hangzhou, CN, 310052
CN Shanghai, CN, 200062
CN Shanghai, CN, 201102
DE Essen, DE, 45147
DE Heidelberg, DE, 69120
ES Esplugues de Llobregat, ES, 08950
ES Madrid, ES, 28041
GB Glasgow, GB, G51 4TF
GB Hampshire, GB, SO16 6YD
GB Manchester, GB, M13 9WL
GB Nottingham, GB, NG7 2UH
IN Bhubaneshwar, IN, 751019
IN Gurgaon, IN, 122001
JP Bunkyo-ku, JP, 113-8431
JP Fuchu-shi, JP, 183-8561
JP Fukuoka-shi, JP, 813-0017
JP Kawasaki-shi, JP, 211-0063
JP Kobe-shi, JP, 650-0047
JP Matsumoto-shi, JP, 390-8621
JP Nakagami-gun, JP, 903-0215
JP Saitama-Shi, JP, 330-8777
JP Sendai-Shi, JP, 989-3126
JP Shizuoka-Shi, JP, 420-8660
PL Białystok, PL, 15-274
PL Łódź, PL, 93-338
PL Warszawa, PL, 02-097
RO București, RO, 022322
RO Cluj-Napoca, RO, 400370
RO Targu Mures, RO, 540136
RO Timisoara, RO, 300011
UA Dnipropetrovsk, UA, 49100
UA Kharkiv region, UA, 61075
UA Kyiv, UA, 04050
UA Sumy, UA, 40031
UA Zaporizhzhia, UA, 69063
US, AL Birmingham, AL, US, 35233
US, MD Baltimore, MD, US, 21287
US, MI Grand Rapids, MI, US, 49503
US, MO Saint Louis, MO, US, 63104
US, NJ Hackensack, NJ, US, 07601
US, OH Akron, OH, US, 44308
US, OH Cincinnati, OH, US, 45229
US, SC Columbia, SC, US, 29203
US, WV Morgantown, WV, US, 26506-7900